The PurpleLab^® Resource Center

The U.S. generic drug supply is at a critical crossroad. With over 60% of generics made abroad, we face a fragile supply chain. This whitepaper analyzes how immediate tariffs to boost domestic manufacturing risk raising patient costs and disrupting access, and outlines the strategic, phased approach needed to secure our drug supply for the long term.

This study was run to characterize patient demographics, cancer indications, treatment patterns, and survival outcomes in a large cohort of patients receiving ADC therapy.

This content was originally published by DeepIntent.  Healthcare marketing is undergoing a transformation, with data-driven insights now serving as the foundation for how brands connect with consumers and providers. That’s why DeepIntent is excited to spotlight PurpleLab®, a data partner that’s helping pharmaceutical brands and agencies connect with their audiences in more effective and meaningful…